Top in women’s health: FDA OKs estradiol gel; surgery improves breast cancer survival

The FDA approved a generic version of estradiol gel to treat moderate to severe vasomotor symptoms.

ANI Pharmaceuticals’ estradiol gel, 0.1%, is a generic version of Divigel (Vertical Pharmaceuticals), an estrogen hormone therapy. The approval was the top story in women’s health last week.

The second top story was about a study in China that showed breast-conserving surgery was associated with high breast cancer survival rates 5 and 10 years after surgery.

Read these and more top stories in women’s health below:

FDA approves generic estradiol gel for vasomotor symptoms due to menopause

ANI Pharmaceuticals received FDA approval for an abbreviated new drug application for estradiol gel, 0.1%, according to a company press release. Read more.

Breast-conserving surgery linked to high survival outcomes for women with breast cancer

Breast-conserving surgery resulted in high overall and disease-free survival rates among patients with breast cancer who underwent surgery in China, according to a cohort study published in JAMA Network Open. Read more.

Potential benefits of midwifery care may suggest need for further implementation in US

Although midwives provide pregnant women with education and support during labor, which may result in a lower intervention likelihood, midwifery care in the U.S. is less utilized compared with other countries. Read more.

Ultrasound useful in assessing spontaneous abortion risk after embryo transfer

Women who undergo embryo transfer and have symptoms of vaginal bleeding should be assessed for risk for spontaneous abortion through pregnancy ultrasound, researchers reported in American Journal of Obstetrics & Gynecology. Read more.

Guideline recommends screening pregnant women at high risk for sleep apnea

A new consensus guideline recommend screening women during pregnancy who have high risk for obstructive sleep apnea, such as those with obesity, hypertension or diabetes. Read more.